SC Placebo

DRUG8 trials

Sponsors

Bausch Health Americas, Inc., Biogen, GlaxoSmithKline, Rhythm Pharmaceuticals, Inc., Merck Sharp & Dohme LLC

Conditions

Advance Illness Patients With OICAdvanced Illness Patients With Opioid Induced ConstipationAsthmaCrohn's DiseaseHealthyHealthy AdultsRelapsing-Remitting Multiple SclerosisUlcerative Colitis

Phase 1

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

CompletedNCT01367535

Bausch Health Americas, Inc.Healthy Adults

Start: 2006-03-31End: 2006-08-31Updated: 2019-11-27

Phase 2

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

CompletedNCT01405820

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2011-08-31End: 2014-10-31Updated: 2015-08-21

Phase 3

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

CompletedNCT00401362

Bausch Health Americas, Inc.Advanced Illness Patients With Opioid Induced Constipation

Start: 2003-02-28End: 2005-02-28Updated: 2019-11-25

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

CompletedNCT00402038

Bausch Health Americas, Inc.Advance Illness Patients With OIC

Start: 2004-02-29End: 2005-10-31Updated: 2019-11-25

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

CompletedNCT01691521

GlaxoSmithKlineAsthma

Start: 2012-10-08End: 2014-01-18Updated: 2018-08-06

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Active, not recruitingNCT06052059

Merck Sharp & Dohme LLCUlcerative Colitis

Start: 2023-10-25End: 2029-08-01Target: 1020Updated: 2026-03-13

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

RecruitingNCT06430801

Merck Sharp & Dohme LLCCrohn's Disease

Start: 2024-06-05End: 2029-11-12Target: 1200Updated: 2026-09-17

Phase 4

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

CompletedNCT05046132

Rhythm Pharmaceuticals, Inc.Healthy

Start: 2021-08-05End: 2022-04-07Updated: 2024-05-03

Related Papers

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Annals of Medicine2024-10-2817 citations

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

ERJ Open Research2024-02-089 citations

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness.

2023-10-201 citations

Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials.

2023-05-0215 citations

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials.

2023-02-101 citations

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation.

2023-01-29

S165 Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

The American Journal of Gastroenterology2022-10-01

Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma.

2022-01-2611 citations

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET

ERJ Open Research2021-10-216 citations

S187 A Pooled Analysis of the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Severe Medical Illness: The Impact of Baseline Opioid Equivalent Dose

The American Journal of Gastroenterology2021-10-01

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.

2021-06-2225 citations

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.

2021-06-1410 citations

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.

2021-06-0736 citations

Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: The impact of baseline ECOG status.

Journal of Clinical Oncology2021-05-20

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.

2021-03-314 citations

S0493 Subcutaneous Methylnaltrexone in Cancer and Non-Cancer Patients for Rapid Relief of Opioid-Induced Constipation

The American Journal of Gastroenterology2020-10-01

Characterising individual response to mepolizumab treatment

2020-09-071 citations

Use of a novel Bayesian borrowing statistical method to assess efficacy of mepolizumab in adolescents

2020-09-07

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.

2020-05-266 citations

Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Advanced-Illness Patients With or Without Active Cancer

Pain Management2020-01-1712 citations

25 more papers not shown